The usefulness of angiogenesis inhibitors has been confirmed in HCC treatment, and it has been pointed out that synergistic effects due to the immunosuppressive action of VEGF/VEGFR can be expected. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.